Cash/Burn From SEC Filing For Period: 

Q1' 20


Coherus BioSciences Inc.

Coherus BioSciences is a leading biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets.



Burn Rate


Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

UDENYCA® (pegfilgrastim-cbqv) Biosimilar


Quarterly Sales (Approved)

November 5, 2020

Humira® (adalimumab) Biosimilar - CHS-1420

Anti-TNF (tumor necrosis factor)

Phase 3 (BLA Filing)

H2 2020

Lucentis® (ranibizumab) Biosimilar

Ophthalmology (anti-VEGF)

Phase 3 (BLA Filing)

H2 2020

Innovent’s Avastin® Biosimilar (bevacizumab)

Non-small-cell lung carcinoma (NSCLC)

Phase 3 (BLA Filing)

Early 2021


Nonalcoholic steatohepatitis (NASH)

Phase 2


Enbrel® (etanercept) Biosimilar

ANTI-TNF (tumor necrosis factor)

Phase 2 (BLA Filing)


Recent Posts

See What The Community Is Saying - Click To See Full Post

CHRS - Coherus BioSciences to ...

#CHRS "announced that its third quarter 2020 financial results will be released after market close on Thursday, November 5, 2020. Starting at 4:30 p.m. EST, Coherus’ management team will host a confer...

CHRS Reports Q2 2020 UDENYCA® ...

#CHRS reports their second quarter of #UDENYCA® Net Sales of $135.7 Million. See our AmpCard for more details. #CHRS, #UDENYCA...

*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon